1h Free Analyst Time
The premenstrual syndrome market is forecasted to grow by USD 276.72 mn during 2023-2028, accelerating at a CAGR of 3.69% during the forecast period. The report on the premenstrual syndrome market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing awareness and reporting about PMS, collaboration and partnerships among vendors, and growing preference for herbal and dietary supplements.
The premenstrual syndrome market is segmented as below:
By Drug Class
- Analgesics
- Oral contraceptives & ovarian suppression agents
- Antidepressants
- Others
By Distribution Channel
- Retail pharmacies
- Hospital pharmacies
- Online pharmacies
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the premenstrual syndrome market covers the following areas:
- Premenstrual syndrome market sizing
- Premenstrual syndrome market forecast
- Premenstrual syndrome market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Drug Class
7 Market Segmentation by Distribution Channel
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
List of Exhibits
Executive Summary
The publisher recognizes the following companies as the key players in the global premenstrual syndrome market: AbbVie Inc., Aspen Pharmacare Holdings Ltd, Bayer AG, Bristol Myers Squibb Co., Eli Lilly and Co., GlaxoSmithKline Plc, Herbalife International of America Inc., Hikma Pharmaceuticals Plc, Johnson and Johnson, Lupin Ltd., Merck KGaA, Novartis AG, Octavius Pharma Pvt. Ltd., Otsuka Pharmaceutical Co. Ltd., Pfizer Inc., Recordati S.p.A, Sanofi SA, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Viatris Inc..Commenting on the report, an analyst from the research team said: 'The latest trend gaining momentum in the market is robust adoption of telemedicine.'
According to the report, one of the major drivers for this market is the increasing awareness and reporting about pms.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc.
- Aspen Pharmacare Holdings Ltd
- Bayer AG
- Bristol Myers Squibb Co.
- Eli Lilly and Co.
- GlaxoSmithKline Plc
- Herbalife International of America Inc.
- Hikma Pharmaceuticals Plc
- Johnson and Johnson
- Lupin Ltd.
- Merck KGaA
- Novartis AG
- Octavius Pharma Pvt. Ltd.
- Otsuka Pharmaceutical Co. Ltd.
- Pfizer Inc.
- Recordati S.p.A
- Sanofi SA
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries Ltd.
- Viatris Inc.
